Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Bed Rest With a Short Cervix on Preterm Birth (BEWISE)

3. Mai 2026 aktualisiert von: Julie Glavind

BEWISE - Bed Rest With a Short Cervix on Preterm Birth

Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.

The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.

The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).

The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.

Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.

Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.

The primary outcome is gestational age in days (continuous).

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

6000

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Pregnant women with gestational age 20+0 to 33+6

  • Cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies
  • Above 18 years of age
  • Reads and understands Danish or English

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Activity Restriction
The comparison arm reflects current Danish clinical practice in each participating region. According to national recommendations, AR is indicated before GA 28+0, with the level of restriction determined by cervical length and clinical context. In singleton pregnancies with a cervix <10 mm in singleton/<15 mm in twins, strict AR is prescribed, defined as bed rest with only toilet allowance. In addition, thrombosis prophylaxis (Low Molecular Weight Heparin and compression stockings) is initiated in cases of strict AR. In women with a cervix of 10-14 mm in singletons/15-20 mm in twins, or in cases of PPROM with a cervix <25 mm, moderate AR is prescribed, defined as 2-8 hours of daily bed rest. The regimen is continued until 28 weeks of gestation.
Recommendation to restrict physical activity in pregnant women with a short cervix. This may include increased rest or bed rest according to local clinical practice.
Andere Namen:
  • AR
  • Bed Rest
Experimental: No Activity Restriction

The intervention consists of a recommendation of NAR during pregnancy. No general or graded restrictions on daily activities are advised, and cervical length is not an indication for activity limitation, in line with current evidence.

The NAR recommendation is supported by a pragmatic clinical guidance. Women are advised to avoid activities that provoke pain, increase uterine contractions, or worsen pelvic pressure. Decisions regarding hospital admission or sick leave are based on individual clinical assessment rather than cervical length.

Specific advice may be provided when clinically indicated. Women are generally advised to avoid heavy weight-bearing exercise and lifting of objects exceeding approximately 10 kg. Otherwise, no specific restrictions on physical activity are imposed, provided that activities do not provoke symptoms such as pain, increased uterine contractions, or pelvic pressure. Sexual activity may be ad-dressed on an individual basis following clinical assessment.

Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.
Andere Namen:
  • Aktivität
  • No Bed Rest
  • NAR

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Gestational age at birth
Zeitfenster: At birth (from inclusion until delivery)
Gestational age at birth measured in completed days of pregnancy. This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).
At birth (from inclusion until delivery)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Birth before 37 weeks of gestation
Zeitfenster: At birth
At birth
Gestational age at birth, pooled
Zeitfenster: At birth (from inclusion until delivery)
  • 14+0-21+6 weeks
  • 22+0-27+6 weeks
  • 28+0-31+6 weeks
  • 32+0-36+6 weeks
  • Birth after 37+0 weeks of gestation
At birth (from inclusion until delivery)
Latency from inclusion to birth (days)
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
Onset of birth
Zeitfenster: At birth (from inclusion until delivery)
  • Spontaneous
  • Induction
  • Caesarean section
At birth (from inclusion until delivery)
Mode of birth
Zeitfenster: At birth (from inclusion until delivery)
  • Vaginal
  • Assisted vaginal
  • Planned caesarean section
  • Non planned caesarean section
At birth (from inclusion until delivery)
- Non-occipital presentation
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
Interventions during birth
Zeitfenster: At birth (from inclusion until delivery)
  • Oxytocin-infusion
  • Epidural anaesthesia
At birth (from inclusion until delivery)
Degree of birth tear
Zeitfenster: At birth (from inclusion until delivery)
  • No tear
  • 1. or 2. degree tear
  • 3. or 4. degree tear
At birth (from inclusion until delivery)
Maternal serious morbidity
Zeitfenster: From inclusion to 42 days after delivery
Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications
From inclusion to 42 days after delivery
Umbilical cord arterial pH
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
EPDS depression score
Zeitfenster: From inclusion to 8 weeks after due date
From inclusion to 8 weeks after due date
Bone turnover marker level
Zeitfenster: At inclusion and after 4 and 8 weeks.
  • Procollagen type 1 N-propeptide (PINP)
  • Carboxy-terminal telopeptide of type I collagen (CTX)
At inclusion and after 4 and 8 weeks.
Lumbar spine Z-score
Zeitfenster: 12 months after stopped breastfeeding
12 months after stopped breastfeeding
Data from SENS activity tracker
Zeitfenster: At birth (from inclusion until delivery)
Step count Time in supine position
At birth (from inclusion until delivery)
Neonatal mortality
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
Fetal loss
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
Birth weight
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)
Neonatal admission, days
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
From inclusion until discharge or 44 postmenstrual weeks
CNS morbidity
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia
From inclusion until discharge or 44 postmenstrual weeks
Gastrointestinal morbidity
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment
From inclusion until discharge or 44 postmenstrual weeks
Respiratory support
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
Mechanical ventilation or non-invasive ventilation (NIV)
From inclusion until discharge or 44 postmenstrual weeks
Respiratory distress syndrome (RDS)
Zeitfenster: From inclusion until discharge or 44 postmenstrual weeks
From inclusion until discharge or 44 postmenstrual weeks
Early onset infection
Zeitfenster: From inclusion to 5 days after birth
Definition: >5 days of i.v. antibiotics where the treatment starts within the first week after delivery.
From inclusion to 5 days after birth
Apgar score at 5 minutes
Zeitfenster: At birth (from inclusion until delivery)
At birth (from inclusion until delivery)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Julie Glavind, Senior Consultant, MD, PhD, Aarhus Univeristy Hospital, Department of Obstetrics and Gynecology

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Mai 2026

Primärer Abschluss (Geschätzt)

1. Februar 2029

Studienabschluss (Geschätzt)

1. Mai 2029

Studienanmeldedaten

Zuerst eingereicht

3. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. Mai 2026

Zuerst gepostet (Tatsächlich)

11. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

IPD will be shared if possible according to GDPR and Danish legislation

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Physische Aktivität

  • Affiliated Hospital to Academy of Military Medical...
    Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University...
    Rekrutierung
    Altersspanne ≥16 Jahre, Geschlecht unbegrenzt | Histopathologie bestätigtes diffuses großzelliges B-Zell-Lymphom oder hochgradiges B-Zell-Lymphom | Erhaltene vorherige Erstlinien-Chemotherapie für DLBCL oder HGBL, CR für vier Zyklen nicht erreicht oder rezidiviert | Mindestens eine... und andere Bedingungen
    China

Klinische Studien zur Activity Restriction

Abonnieren